A new systematic review and updated orthopedic guidance create timely, local treatment-intent content. This article was evidence-checked on September 6, […]

Tirzepatide and birth control require extra planning when the contraceptive is taken by mouth. The current FDA prescribing information advises […]

Forzinity FDA approval has created understandable questions about elamipretide, Barth syndrome and products marketed as “SS-31.” The central distinction is […]

Phase 3 head-to-head results and an anticipated late-2026 FDA decision create strong news and comparison intent. This article was evidence-checked […]

Regulatory safety updates and new observational research are driving urgent patient questions about vision loss. This article was evidence-checked on […]

Evidence review date: September 6, 2026. GLP-1 microdosing has attracted substantial consumer and telehealth interest, but direct clinical-trial evidence remains […]